Exanthema after a stress Tc-99m sestamibi study: continue with a rest sestamibi study?

Area of Science:

• Nuclear Medicine
• Radiopharmaceuticals
• Cardiology

Background:

• Myocardial perfusion imaging (MPI) is crucial for assessing coronary artery disease.
• Tc-99m sestamibi is a commonly used radiopharmaceutical for MPI.
• Adverse events (AEs) during MPI, though rare, require careful management.

Observation:

• A patient developed a mild maculo-papular exanthema, suspected to be an allergic reaction, after Tc-99m sestamibi injection during stress MPI.
• A subsequent rest MPI was necessary to guide surgical decisions.
• The patient received prophylactic antihistamine and corticosteroid treatment before the rest MPI.

Findings:

• The rest MPI was successfully completed without further adverse events after prophylactic treatment.
• This case highlights the potential for allergic reactions to Tc-99m sestamibi.
• The absence of specific guidelines for managing AEs in nuclear medicine is noted.

Implications:

• Premedication with antihistamines and corticosteroids can mitigate allergic reactions to Tc-99m sestamibi.
• Standardized protocols for managing allergic reactions in nuclear medicine are needed.
• Physicians should be prepared to manage potential AEs during radiopharmaceutical administration, following general allergy treatment guidelines.